The agreement with Alumni Capital LP provides Kazia Therapeutics with a financial mechanism to raise up to $15M through the sale of American Depositary Shares. This influx of capital could be used for operational expenses, research and development, or expansion activities, which in turn could positively impact the company's stock price in the short term by improving its financial health and growth prospects.